Epilepsy Disease and Nose-to-Brain Delivery of Polymeric Nanoparticles: An Overview

Epilepsy is the fourth most common global neurological problem, which can be considered a spectrum disorder because of its various causes, seizure types, its ability to vary in severity and the impact from person to person, as well as its range of co-existing conditions. The approaches to drug thera...

Full description

Saved in:
Bibliographic Details
Main Authors: Teresa Musumeci (Author), Angela Bonaccorso (Author), Giovanni Puglisi (Author)
Format: Book
Published: MDPI AG, 2019-03-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_9b896f1a7a5e4fe7a6e7a7e721efaa8b
042 |a dc 
100 1 0 |a Teresa Musumeci  |e author 
700 1 0 |a Angela Bonaccorso  |e author 
700 1 0 |a Giovanni Puglisi  |e author 
245 0 0 |a Epilepsy Disease and Nose-to-Brain Delivery of Polymeric Nanoparticles: An Overview 
260 |b MDPI AG,   |c 2019-03-01T00:00:00Z. 
500 |a 1999-4923 
500 |a 10.3390/pharmaceutics11030118 
520 |a Epilepsy is the fourth most common global neurological problem, which can be considered a spectrum disorder because of its various causes, seizure types, its ability to vary in severity and the impact from person to person, as well as its range of co-existing conditions. The approaches to drug therapy of epilepsy are directed at the control of symptoms by chronic administration of antiepileptic drugs (AEDs). These AEDs are administered orally or intravenously but alternative routes of administration are needed to overcome some important limits. Intranasal (IN) administration represents an attractive route because it is possible to reach the brain bypassing the blood brain barrier while the drug avoids first-pass metabolism. It is possible to obtain an increase in patient compliance for the easy and non-invasive route of administration. This route, however, has some drawbacks such as mucociliary clearance and the small volume that can be administered, in fact, only drugs that are efficacious at low doses can be considered. The drug also needs excellent aqueous solubility or must be able to be formulated using solubilizing agents. The use of nanomedicine formulations able to encapsulate active molecules represents a good strategy to overcome several limitations of this route and of conventional drugs. The aim of this review is to discuss the innovative application of nanomedicine for epilepsy treatment using nose-to-brain delivery with particular attention focused on polymeric nanoparticles to load drugs. 
546 |a EN 
690 |a poly-lactide-co-glycolide 
690 |a nanocarrier 
690 |a intranasal 
690 |a epilepsy 
690 |a brain 
690 |a pharmaceutical nanotechnology 
690 |a anti-epiletic drug 
690 |a nose to brain 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 11, Iss 3, p 118 (2019) 
787 0 |n http://www.mdpi.com/1999-4923/11/3/118 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/9b896f1a7a5e4fe7a6e7a7e721efaa8b  |z Connect to this object online.